Summary
The use of adjuvant chemotherapy in women with node-negative breast cancer has been controversial and actively debated since the 1988 National Cancer Institute Clinical Alert. We developed a decision analysis model that used the results of available randomized controlled trials to assess the potential clinical and financial effects of using adjuvant chemotherapy for groups of 45-year-old and 60-year-old women. Using the baseline assumptions, we found that chemotherapy increases quality adjusted life expectancy and survival by a substantial amount at a cost comparable to most accepted medical interventions. The model highlights the uncertainties in duration of benefit from therapy, the need for refinements in risk stratification, the importance of patient preferences about toxicity and benefit, and the need for accurate cost-accounting for oncologic therapies. Decision analysis complements other methods for information gathering, analysis, and synthesis used in clinical research. With the increasing focus on the effectiveness of medical interventions, decision analysis will be an important tool for oncologists to understand.
Similar content being viewed by others
References
National Cancer Institute: Clinical Alert, May 16–18, 1988. NCI, Bethesda, 1988
Devita VT: Breast cancer therapy: exercising all our options. N Engl J Med 320:527–529, 1989
McGuire WL: Adjuvant therapy of node-negative breast cancer. N Engl J Med 320:525–527, 1990
Ingle JN: Assessing the risk of recurrence in breast cancer. N Engl J Med 322:329–331, 1990
Henderson IC: Adjuvant systemic therapy: State of the art, 1989. Breast Cancer Res Treat 14:3–22, 1989
Hillner BE, Smith TJ: Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model. N Engl J Med 324:160–168, 1991
Pauker SG, Kassirer JP: Decision analysis. N Engl J Med 316:250–258, 1987
Rosen PP, Groshen S, Saigo PE, Kinne DW, Hellman S: A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol 7:355–366, 1989
Carter CL, Allen C, Henson DE: Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63:181–187, 1989
NIH Consensus Conference: Treatment of early-stage breast cancer. JAMA 265:391–395, 1991
Bonadonna G: Karnofsky memorial lecture. Conceptual and practical advances in the management of breast cancer. J Clin Oncol 7:1380–1397, 1989
Norton L: Implications of kinetic heterogeneity in clinical oncology. Semin Oncol 3:231–249, 1985
Norton L: Kinetic concepts in the treatment of breast cancer. Breast Cancer Res Treat, in press
Tannock IF: Adjuvant therapy for node-negative breast cancer. N Engl J Med 321:471, 1989
Levine MN, Guyatt GH, Gent M, et al: Quality of life in stage II breast cancer: an instrument for clinical trials. J Clin Oncol 6:1798–1810, 1988
Levine MN: Quality of life in breast cancer.In Osoba D (ed) Effect of Cancer on Quality of Life. CRC Press, Boca Raton, 1991, pp 205–214
Goldhirsch A, Gelber RD, Simes RJ, Glasziou P, Coates AS: Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. J Clin Oncol 7:36–44, 1989
Gelber RD, Goldhirsch A, Cavalli F: Quality-of-life-adjusted evaluation of adjuvant therapies for operable breast cancer. The International Breast Cancer Study Group. Ann Intern Med 114:621–628, 1991
McGuire WL, Tandon AK, Allred DC, Chamness GC, Clark GM: How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst 82:1006–1015, 1990
Simes RJ, Cocker K, Glasziou P, Coates AS, Tattersall MH: Costs and benefits of adjuvant chemotherapy for breast cancer: an assessment of patient preferences [abstract]. Proc Am Soc Clin Oncol 8:52A, 1989
Baker MS, Kessler LG, Urban N, Smucker RC: Estimating the treatment costs of breast and lung cancer. Med Care 29:40–49, 1991
Detsky AS, Nagle T: A clinician's guide to cost-effectiveness analysis. Ann Intern Med 113:147–154, 1990
Drummond MF, Stoddart GL, Torrance GW: Methods for the Evaluation of Health Care Programmes. Oxford University Press, Oxford, 1987, p 39
Gelber RD, Goldhirsch A: The concept of an overview of cancer clinical trials with special emphasis on early breast cancer. J Clin Oncol 4:1696–1703, 1986
Institute of Medicine: Breast Cancer: Setting Priorities for Effectiveness Research. IOM, Washington DC, 1990
Hillner BE, Smith TJ, Desch CE: Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer — Estimates using decision analysis while awaiting clinical trial results. JAMA 267:2055–2061, 1992
Siminoff LA, Fetting JH: Effects of outcome framing on treatment decisions in the real world: Impact of framing on adjuvant breast cancer decisions. Med Decis Making 9:262–261, 1989
Fetting JH, Siminoff LA, Piantadosi S, Abeloff MD, Damron DJ, Sarsfield AM: Effect of patients' expectations of benefit with standard breast cancer adjuvant chemotherapy on participation in a randomized clinical trial: a clinical vignette study. J Clin Oncol 8:1476–1482, 1990
Hillner BE, Smith TJ: Estimating the efficacy and cost-effectiveness of tamoxifen compared to tamoxifen plus chemotherapy in node-positive, estrogen receptorpositive postmenopausal women. International Conference on Long-Term Anti-Estrogen Therapy, Orlando, Florida, June 30, 1991
Detsky AS: What's wrong with decision analysis? Can the left brain influence the right? J Clin Epidemiol 40:831–836, 1987
Welch HG, Larson EB: Cost effectiveness of bone marrow transplantation in acute nonlymphocytic leukemia. N Engl J Med 321:807–812, 1989
Weinstein MC, Stason WB: Cost-effectiveness of coronary artery bypass surgery. Circulation 66(Suppl III):56–66, 1982
Edelson JT, Weinstein MC, Tosteson ANA, Williams L, Lee TH, Goldman L: Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA 263:407–413, 1990
Strange PB, Sumner AT: Predicting treatment costs and life expectancy for end-stage renal disease. N Engl J Med 298:372–378, 1978
Eddy DM: Screening for breast cancer. Ann Intern Med 111:389–399, 1989
Weeks JC, Tierney MR, Weinstein MC: Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med 325:81–86, 1991
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hillner, B.E., Smith, T.J. Should women with node-negative breast cancer receive adjuvant chemotherapy? — Insights from a decision analysis model. Breast Cancer Res Tr 23, 17–27 (1992). https://doi.org/10.1007/BF01831472
Issue Date:
DOI: https://doi.org/10.1007/BF01831472